List of publications using BEZ 235 (Axon 1281) purchased from Axon Medchem
(total 33 publication citations listed from 2009 to AUGUST- 2017)
2017
Muranen, T., Iwanicki, M. P., Curry, N. L., Hwang, J., DuBois, C. D., Coloff, J. L., ... & Kalaany, N. Y. (2017). Starved epithelial cells uptake extracellular matrix for survival. Nature communications, 8, 13989.
https://www.nature.com/
Otani, R., Mukasa, A., Shin, M., Omata, M., Takayanagi, S., Tanaka, S., ... & Saito, N. (2017). Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. Journal of Neurosurgery, 1-10.
http://thejns.org/doi/abs/10.
Albeck, J. G., Hung, Y. P., Teragawa, C., Pargett, M., Gillies, T. E., Minguet, M., ... & Yellen, G. (2017). Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. bioRxiv, 126771.
http://www.biorxiv.org/
(BEZ235, BMK120, GDC0941 and Gefitinib from Axon Medchem)
Muranen, T., Selfors, L. M., Hwang, J., Gallegos, L. L., Coloff, J. L., Thoreen, C. C., ... & Brugge, J. S. (2016). ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer research, 76(24), 7168-7180.
http://cancerres.aacrjournals.
Bhatia, D. R., & Thiagarajan, P. (2016). Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer. Hypoxia, 4, 163.
https://www.ncbi.nlm.nih.gov/
Mediani, L., Gibellini, F., Bertacchini, J., Frasson, C., Bosco, R., Accordi, B., ... & Sgarbi, G. (2016). Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/mTOR signaling. Oncotarget, 7(5), 5521.
https://www.ncbi.nlm.nih.gov/
Kim, Min-Jung, et al. "Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation." Journal of Korean medical science 31.3 (2016): 360-370.
http://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2016.31.3.360
http://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0473-7
http://mct.aacrjournals.org/content/14/5/1095.short
*BEZ235 and AZD8055 are from Axon Medchem.
https://www.google.com/patents/US8859548
*PD0325901, PD184352, SL327, LY294002, PI103, PIK75, PIK90, GDC0941, BEX235, AS252424, TGX221 are from Axon Medchem
https://www.google.com/patents/US8748428
* LY294002, PI103, PIK75, PIK90, AS252424, TGX221, GDC0941 are from Axon Medchem.
CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, T Sim, DM Sabatini, NS Gray.
J. Biol. Chem. 2009, 284, 8023-8032. DOI: 10.1074/jbc.M900301200
[Citation: 338, till August 9, 2012]
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, F C Geyer, M van Kouwenhove, B Kreike, A Mackay, A Ashworth, MJ van de Vijver, JS Reis-Filho.
Oncogene, 2010, 29, 2013–202. doi:10.1038/onc.2009.489
[Citation: 63, till August 9, 2012]
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia.
F Chiarini, C Grimaldi, F Ricci, PL Tazzari, C Evangelisti, A Ognibene, M Battistelli, E Falcieri, F Melchionda, A Pession, P Pagliaro, JA McCubrey, AM Martelli.
Cancer Res. 2010, 7, 8097. doi: 10.1158/0008-5472.CAN-10-1814
[Citation: 37, till August 9, 2012]
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells.
J Sunayama,, KI Matsuda, A Sato, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka.
STEM CELLS, 2010, 28, 1930–1939. DOI: 10.1002/stem.521
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
J Sunayama, A Sato, KI Matsuda, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka.
Neuro. Oncol. 2010,12 (12), 1205-1219. DOI: 10.1093/neuonc/noq103
The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
D Castelletti, G Fiaschetti, V Di Dato, U Ziegler, C Kumps, K De Preter, M Zollo, F Speleman, T Shalaby, D De Martino, T Berg, A Eggert, A Arcaro, MA Grotzer.
Mol. Cancer Ther. 2010, 9, 3145. DOI: 10.1158/1535-7163.MCT-10-0539
BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell Backgrounds.
CB Carlson, MJ Mashock and K Bi
J. Biomol. Screen. 2010, 15 (3) 327-334. doi: 10.1177/1087057109357788
Aberrant AKT activation drives well-differentiated liposarcoma.
A Gutierrez, EL Snyderc, A Marino-Enriquez, YX Zhang, S Sioletic, E Kozakewich, R Grebliunaite, WB Ou, E Sicinska, CP Raut, GD Demetri, AR Perez-Atayde, AJ Wagner, JA Fletcher, CDM Fletcher, AT Look.
PNAS, 2011, 108 (39), 16386-16391. DOI: 10.1073/pnas.1106127108
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
ACP de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber, BL Fiebich.
J. Neuroinflam. 2012, 9, 2. DOI:10.1186/1742-2094-9-2
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
DT Worster, T Schmelzle, NL Solimini, ES Lightcap, B Millard, GB Mills, JS Brugge, JG Albeck,
Sci. Signal. 2012, 5(214), ra19. DOI: 10.1126/scisignal.200198
Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
C Stengel, CW Cheung, J Quinn, K Yong, A Khwaja. - nature.com -
Leukemia, 2012, 1–10. DOI: 10.1038/leu.2012.69
Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis
RD Fevurly, S Hasso, A Fye, SJ Fishman, J Chan.
J. Pediatric Surgery, 2012, 47 (1), 177–182. [online]
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
AC de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber and BL Fiebich.
J. Neuroinflammatory. 2012, 9, 2. [online]
Compounds and compositions as protein kinase inhibitors.
AQ Costales, S Huang, JX Jin, Z Liu, S Pecchi, D Poon, J Tellew, and Q Zhang.
U.S. Patent 8,242,260, issued August 14, 2012.
HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS.
AM Madera, D Poon, and A Smith.
U.S. Patent No. 20,130,096,149. 18 Apr. 2013.
Next‐generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN‐amplified neuroblastoma.
A Schramm, J Köster, T Marschall, M Martin, M Schwermer, K Fielitz, G Büchel, M Barann, D Esser, P Rosenstiel, S Rahmann, A Eggert, JH Schulte.
Int. J. Cancer 2013, 132 (3), E106-E115.
Read more: http://onlinelibrary.wiley.com/doi/10.1002/ijc.27787/full
PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.
J Tan, Z Li, PL Lee, P Guan, MY Aau, ST Lee, M Feng, CZ Lim, EYJ Lee, ZN Wee, YC Lim, RKM Karuturi and Q Yu.
Cancer Discovery, Published Online July 25, 2013.
Read more: http://www.ncbi.nlm.nih.gov/pubmed/23887393
... 60 inhibitors including BEZ235 were purchased from Axon Medchem
Compounds and Compositions as Protein Kinase Inhibitors
US 20140011825 A1
Read more: http://www.google.com/patents/US20140011825
Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity.
Pais, F., Lee, S., Rodic, V., Barth, M. J., Cairo, M. S., & Hermiston, M. L. (2013).
Blood, 122(21), 243-243.
Read more: http://bloodjournal.hematologylibrary.org/content/122/21/243.short
Chondrosarcoma models: understanding chemoresistance mechanisms for use in targeted treatment
Oosterwijk, J. G. V. (2013).
(Doctoral dissertation, Department of Pathology, Faculty of Medicine, Leiden University Medical Center (LUMC).
Read more: https://openaccess.leidenuniv.nl/handle/1887/22281
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.
J Kawasaki, S Aegerter, RD Fevurly, A Mammoto, T Mammoto, M Sahin, JD Mably, SJ Fishman and J Chan.
J Clin Invest. 2014, doi:10.1172/JCI67084.
* GDC0941 and BEZ235 from Axon Medchem
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
S Zhou, L Liu, H Li, G Eilers, Y Kuang, S Shi, Z Yan, X Li, JM Corson, F Meng, H. Zhou, Q Sheng, JA Fletcher, WB Qu.
Br. J. Cancer (2014) 110, 2479–2488. doi:10.1038/bjc.2014.220 www.bjcancer.com
Read more: http://www.nature.com/bjc/journal/v110/n10/full/bjc2014220a.html
(This is an incomplete list, updated in AUGUST-2017)
